首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL17D |
| Uniprot No | Q8TAD2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-202aa |
| 氨基酸序列 | APRAGRRPAR PRGCADRPEE LLEQLYGRLA AGVLSAFHHT LQLGPREQAR NASCPAGGRP ADRRFRPPTN LRSVSPWAYR ISYDPARYPR YLPEAYCLCR GCLTGLFGEE DVRFRSAPVY MPTVVLRRTP ACAGGRSVYT EAYVTIPVGC TCVPEPEKDA DSINSSIDKQ GAKLLLGPND APAGP |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-17D重组蛋白的3篇参考文献及其摘要概括：
1. **《IL-17D: A novel mediator of antiviral immunity and tumor surveillance》**
- **作者**: Li H, et al.
- **摘要**: 研究发现IL-17D重组蛋白通过激活NK细胞和促进IFN-γ分泌，增强宿主对病毒感染和肿瘤的免疫应答，揭示了其在先天免疫中的关键作用。
2. **《Recombinant IL-17D modulates endothelial cell function and angiogenesis》**
- **作者**: Smith JJ, et al.
- **摘要**: 通过体外实验证实，IL-17D重组蛋白能够诱导内皮细胞分泌促血管生成因子(如VEGF)，并调控血管生成相关信号通路，提示其在血管疾病中的潜在应用。
3. **《Structural and functional characterization of recombinant human IL-17D》**
- **作者**: Garcia KC, et al.
- **摘要**: 通过X射线晶体学解析了IL-17D重组蛋白的三维结构，并证明其通过结合特异性受体激活下游炎症信号通路，为靶向药物开发提供了结构基础。
注：以上文献为示例，实际文献需通过PubMed或Google Scholar以“IL-17D recombinant protein”为关键词检索最新研究。
IL17D is a member of the interleukin-17 (IL-17) cytokine family, which plays critical roles in immune regulation and inflammatory responses. Discovered in 2002. IL17D shares structural homology with other IL-17 family members (IL-17A to IL-17F) but exhibits distinct expression patterns and functional characteristics. Unlike IL-17A and IL-17F, which are primarily produced by T cells and drive pro-inflammatory responses, IL17D is broadly expressed in epithelial cells, endothelial cells, and certain immune cells, suggesting a unique regulatory role in tissue homeostasis and pathogen defense.
Recombinant IL17D protein is engineered using mammalian or bacterial expression systems to enable functional studies. Its production involves cloning the IL17D gene into expression vectors, followed by purification via affinity chromatography. This recombinant form retains the ability to bind putative receptors, such as IL-17RA or IL-17RB, although its receptor complex and downstream signaling pathways remain less defined compared to other IL-17 cytokines.
Emerging research highlights IL17D's dual role in immunity. It promotes anti-tumor responses by enhancing natural killer (NK) cell activity and chemokine production, yet it may also suppress excessive inflammation in autoimmune contexts. Preclinical studies suggest therapeutic potential in cancer immunotherapy and chronic inflammatory diseases, though its precise mechanisms and clinical relevance require further exploration. Challenges include clarifying receptor interactions, tissue-specific effects, and reconciling contradictory findings across disease models. As a relatively understudied cytokine, IL17D represents a promising target for unraveling novel immune pathways and developing targeted therapies.
×
